Welcome to Meta-IQ

Meta-IQ is a Danish biotech company that develops innovative treatment for Acute ocular neuritis (AON)  and  Secondary progressive multiple sclerosis (SP-MS)  by inhibiting CPT1 (the key molecule in fat metabolism) and thus resetting the energy metabolism from fatty-acid back to glucose resulting in neuro-protective and anti-inflammatory properties. Meta-IQ has reached proof of concept in animal models for the small molecule compound MIQ-001. MIQ-001 is working via a new mode of action and has shown exceptional efficacy in these diseases, with findings independently confirmed by leading international researchers.

News and Events

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.